Shopping Cart
Remove All
Your shopping cart is currently empty
Verekitug is a novel, recombinant, fully human monoclonal antibody developed to selectively target thymic stromal lymphopoietin receptor (TSLPR) with high potency. Verekitug is currently being investigated as a potential therapeutic candidate for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), where overactivation of TSLPR contributes to disease pathology. Verekitug offers a promising approach to immune modulation in respiratory and inflammatory disease research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $198 | - | In Stock | |
| 5 mg | $645 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,460 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock |
| Description | Verekitug is a novel, recombinant, fully human monoclonal antibody developed to selectively target thymic stromal lymphopoietin receptor (TSLPR) with high potency. Verekitug is currently being investigated as a potential therapeutic candidate for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), where overactivation of TSLPR contributes to disease pathology. Verekitug offers a promising approach to immune modulation in respiratory and inflammatory disease research. |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CRLF2 |
| Molecular Weight | 144.05 kDa |
| Cas No. | 2768386-15-6 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.